# Imipenem Versus Cefepime in Spontaneous Bacterial Peritonitis and to Evaluate the Risk Factors for Treatment Failure

> **NCT01852630** · NA · COMPLETED · sponsor: **Institute of Liver and Biliary Sciences, India** · enrollment: 175 (actual)

## Conditions studied

- Spontaneous Bacterial Peritonitis

## Interventions

- **DRUG:** cefepime + Albumin
- **DRUG:** Imipenem + Albumin

## Key facts

- **NCT ID:** NCT01852630
- **Lead sponsor:** Institute of Liver and Biliary Sciences, India
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 175 (ACTUAL)
- **Last updated:** 2016-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01852630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01852630, "Imipenem Versus Cefepime in Spontaneous Bacterial Peritonitis and to Evaluate the Risk Factors for Treatment Failure". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01852630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*